Routine Health Screenings (https://www.myeloma.org/health-screenings)
Routine Health Screenings
Due to new therapeutic options, patients with newly diagnosed and relapsed multiple myeloma are living longer than they did just one decade ago. Therefore, patients' general health must also be maintained throughout the course of their disease. Proper maintenance of pre-existing or co-morbid conditions can improve quality of life and extend survival.
The following is a description of additional health issues that multiple myeloma patients may face along with the screening recommendations for each.
Cardiovascular
| Health Condition | Diagnosis | Frequency of Screening | Prevention* |
| Hypertension (high blood pressure) | Determined upon the average of two or more properly measured readings at each of two or more office visits after an initial screening. Hypertension blood pressure readings show a systolic of 140 mmHg or higher and diastolic of 90 mmHg or higher
| "The USPSTF suggests annual screening for hypertension in adults 40 years or older and for adults at increased risk for hypertension(such as Black persons, persons with high-normal blood pressure, or persons who are overweight or obese). Screening less frequently (ie, every 3 to 5 years) is appropriate for adults aged 18 to 39 years not at increased risk for hypertension and with a prior normal blood pressure reading."
| Prevention:
Low sodium diet Reduced alcohol consumption Increased physical activity
|
Hyperlipidemia
| Diagnosed by the results of a fasting lipoprotein profile including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol (HDL), and triglycerides.
| Men older than 35: every 5 years (if results are normal) Men aged 20-35: every 5 years unless they are at increased risk for heart disease Women older than 20: screen only if at an increased risk for heart disease
|
Dietary changes Regular physical activity Smoking prevention or cessation
|
* Depending on a patient’s co-morbid conditions, the treatment of hypertension varies. Multiple myeloma patients who are diagnosed with hypertension should discuss the treatments they require with a cardiovascular specialist.
** The U.S. Preventative Services Task Force makes no recommendations for or against routine screening for lipid disorders in men ages 20-35 or in women ages 20 or older who are not at risk for coronary heart disease.
More information and guidelines can be found at:
• American Heart Association (https://www.heart.org/)
• 2025 Guidelines by the American College of Cardiology/American Heart Association (ACC/AHA) (https://www.ahajournals.org/doi/10.1161/CIR.0000000000001383)
• National Cholesterol Education Program from the National Institutes of Health (https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf)
Malignancies
Multiple myeloma patients should continue to be screened for other malignancies throughout the course of their disease, especially if they have a genetic predisposition to other cancers. Some patients do develop secondary cancers. Proper screening and preventative measures can treat these malignancies should they develop.
| Health Condition | Screening Process |
| Breast Cancer (Overproduction of cells in the breast that develop into a cancerous tumor) | The U.S Preventatitve Task Force recommends that all women get screened for breast cancer every other year, starting at age 40 and continuing through age 74, to reduce their risk of dying from this disease. This is a B grade. In this final recommendation statement (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening), they urgently call for more research that will allow us to build on our existing guidance and help all women live longer and healthier lives. Specifically, there is a need to know how best to address health disparities across screening and treatment experienced by Black, Hispanic, Latina, Asian, Pacific Islander, Native American, and Alaska Native women. They also call for studies on what more should be done for women with dense breasts as well as evidence on the benefits and harms of screening in older women
|
| Cervical Cancer (Abnormal cells of the cervix -the canal between the uterus and vagina) | "The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (co-testing)." |
Skin Cancer
| Screening: A = asymmetry (one half of the mole does not match the other half).
.
Yet in 2016, the USPSTF found insufficient evidence to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer in adults, and this has not been updated. |
| Colorectal Cancer (Abnormal cells in the colon or rectum) | Stool Test: checks for the presence of blood in the stool Colonoscopy: To check inside the colon and rectum for abnormalities Flexible sigmoidoscopy: To check the lower colon for abnormalities Multi-targeted stool DNA testing: stool sample that checks for DNA mutations and blood CT colonography: Using X-rays to see images of the colon The USPSTF recommends screening for colorectal cancer (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening) in all adults aged 50 to 75 years. The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences.
|
| Prostate Cancer (Abnormal cells in the prostate) | Two types of screening: 1. Prostate-specific antigen (PSA) blood test: Checks for high amounts of PSA. However high PSA does not always indicate prostate cancer 2. Digital rectal exam: doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for lumps or anything else unusual For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening. The USPSTF recommends against PSA-based screening (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening)for prostate cancer in men 70 years and older.
|
More information and guidelines can be found at:
- U.S. Preventative Services Task Force (USPTF) guidelines and recommendations for the screening of breast cancer. (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening)
- USPTF guidelines and recommendations for the screening of cervical cancer. (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening)
- USPSTF's guidelines and recommendations for the screening of skin cancer. (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-screening)
- USPSTF's guidelines and recommendations for the screening of colorectal cancer. (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening)
- USPSTF's guidelines and recommendations for the screening of prostate cancer. (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening)
Endocrine Disorders
| Health Condition | What Is It? | Screening Process |
Diabetes Mellitus Type 2
| The pancreas struggles to produce enough insulin. Myeloma patients have increased blood sugar levels, especially those on a long-term steroid therapy treatment.
| Various kinds of blood tests, including: A1C (reflects average blood sugar levels for the past 2-3 months) Glucose tolerance test (determines how well your body processes sugar) Fasting blood glucose |
| Thyroid Dysfunction | The thyroid cannot make enough of the correct hormones | Blood tests that measures the amount of TSH (Thyroid Stimulating Hormone) in the blood. Also known as a serum TSH test. |
*Patients receiving treatment for multiple myeloma can have an increased incidence of hyperglycemia (high blood sugar) when dexamethasone is incorporated into their regimen. The incidence of high blood sugar is actually prevalent in all steroid users.
More information and guidelines can be found at:
• USPSTF guidelines and recommendations for the screening of Type 2 Diabetes. (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes)
• USPSTF guidelines and recommendations for the screening of Thyroid Dysfunction. (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/thyroid-dysfunction-screening)
Sensory Health
| Health Benefits | What Is it? | Screening Process |
| Vision issues | Multiple myeloma patients with comorbidities such as diabetes, hypertension, or a family history of ocular disease, may be at greater risk for vision health issues. | Routine vision checks as advised by a healthcare professional |
| Hearing issues | Most patients with multiple myeloma are older adults with a median age at diagnosis between ages 68 to 70. Therefore, screening for hearing loss is essential. | Frequency: Before age 50, tests should be conducted every 10 years Patients 50 and older should be screened every 3 years |
More information and guidelines can be found at:
• National Eye Institute (https://www.nei.nih.gov/)
• American Academy of Ophthalmology (https://www.aao.org/)
Addiction and Substance Abuse
| Health Condition | Screening Process | How is it treated? |
Smoking Can also cause other cancers Increases the risk of pulmonary infections
| Health care providers will ask if you are an active smoker
| Counseling following guidelines to stop the use of tobacco in myeloma patients
|
Alcohol Contributes to increased risk for liver disease, high blood pressure, inflammation of the pancreas, cancer, and mental dysfunction
| Health care providers will ask if you about your alcohol consumption
| Counselling: Face-to-face sessions Written self-help materials Computer-based programs Telephone counselling During counseling, healthcare professionals work with patients on various strategies, such as action plans, drinking diaries, stress management, and problem-solving. |
More information and guidelines can be found at:
• USPSTF guidelines and recommendations for the screening of Alcohol Misuse (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions). (https://www.uspreventiveservicestaskforce.org/uspstf/draft-update-summary/unhealthy-alcohol-use-adolescents-adults-behavioral-counseling-interventions)
Vaccines
| Type of Immunization | Why It's Important for Myeloma Patients |
| Influenza Vaccine | For the general population, but also essential for immunocompromised (myeloma) patients. Should be offered in early autumn, however, can be offered year-round when an outbreak is detected in the community. |
| Pneumococcal Vaccine | Immunocompromised patients with multiple myeloma are at risk for developing pneumococcal disease. 1. the pneumococcal polysaccharide vaccine 2. the pneumococcal conjugate vaccine |
Tetanus Booster
| Recommended every 10 years |
| Post-transplantation vaccinations | After transplantation, a patient remains immunocompromised for 6-12 months. Immunizations such as polio, tetanus toxoid, diphtheria toxoid, pneumococcus, hepatitis B, haemophilus influenzae type B conjugate, and measles, mumps, and rubella, should be given to the patient as per the recommendations of the transplantation center. |
| Coronavirus Vaccine | Learn more about COVID-19 Vaccinations and Myeloma Patients here (https://www.myeloma.org/covid19-myeloma-patients/covid-19-faq) |
Oral Hygiene
| Oral Hygiene Health | Screening | Risk Factors |
General dental care includes brushing teeth twice daily, cleaning between the teeth daily with floss or an interdental cleaner, and seeing the dentist regularly for examinations (including X-rays, if warranted), and professional cleaning. Minimum twice-yearly visits to the dentist is required to maintain good oral hygiene. For myeloma patients there is risk of reduced blood flow to the bone in the jaw which can be prevented, diagnosed, and treated by an oral health care provider | Direct inspection and palpation (feeling with the fingers or hands) of the oral cavity is the most recommended method of screening for oral cancer, which can be completed by a dentist during routine visits.
| Smoking: increases risk for oral cancer
|
More information and guidelines can be found at:
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologists, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape.
Additionally, the content on this page is medically reviewed by myeloma physicians and healthcare professionals.
Last Medical Review: October 7, 2026